Other
Ferric carboxymaltose
Brand: Ferinject®
PBAC's latest decision on Ferric carboxymaltose: Recommended (2018). Considered for Treatment of iron deficiency anaemia (IDA).
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
2013 → 2018
Eligible population
Patients requiring intravenous iron treatment for iron deficiency anaemia, particularly those who would typically receive a 1,000 mg dose.
- Therapy area
- Other
- Line of therapy
- Not applicable
- Evidence base
- Cost-minimisation
- Primary endpoint
- Cost-minimisation
- Economic model
- Cost-minimisation
- ICER note
- This is a minor submission for an additional strength presentation; no economic evaluation conducted.
Submission history
- Mar 2013: Recommended · Unrestricted
- Nov 2013: Recommended · Unrestricted
- Nov 2018: Recommended · Unrestricted
Similar precedents
Open on full dashboard →